A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living With HIV-1
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; VRC 01LS (Primary) ; Antiretrovirals; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 06 Nov 2019 Planned End Date changed from 24 Oct 2022 to 2 Dec 2022.
- 06 Nov 2019 Planned primary completion date changed from 30 Oct 2020 to 2 Nov 2021.
- 06 Nov 2019 Planned initiation date changed from 4 Nov 2019 to 2 Dec 2019.